s KEY POINTS
The lesion of calcific aortic stenosis shares histologic similarities with atheromatous coronary artery disease, and its development and progression are linked to various traditional risk factors for atherosclerosis.
For unclear reasons, only about 40% of patients with calcific aortic stenosis also have coronary artery disease, and most people with coronary artery disease do not have calcific aortic stenosis.
Hypertension, smoking, and diabetes mellitus have consistently been linked to the development of aortic stenosis. Endothelial injury or other processes that contribute to coronary disease may play a similar role in calcific aortic stenosis.
In observational studies, aortic stenosis progressed at a slower rate in patients who received statin drugs than in those who did not.
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CME s AGING NOT THE ONLY CAUSE
The debate over the pathogenesis of nonrheumatic calcific aortic stenosis (ie, stenosis of a trileaflet aortic valve) dates back to 1904, when Mönckeberg first described dystrophic calcification of the aortic valve. 16 The conventionally accepted hypothesis has been that with age, repeated mechanical stimuli and hemodynamic forces lead to leaflet injury and dystrophic calcification. 1, 2, 17 Although age-related changes in the valve do occur, 3 aging should not be considered synonymous with aortic valve disease, because many elderly people do not develop aortic stenosis. 11 Moreover, over the last decade, studies have linked the development and progression of calcific aortic valve disease to various traditional risk factors for atherosclerosis. Further support for the hypothesis that the condition is not just age-related comes from the work of Otto et al 3 and O'Brien et al, 4 who found that the "early lesion" of aortic stenosis is microscopically similar to atheroma in several ways.
Nevertheless, key questions remain: • Nearly 40% of patients with aortic valve stenosis also have significant coronary artery disease, defined as a narrowing of the luminal diameter of an epicardial coronary artery of 70% or more. 18 • Elevated low-density lipoprotein (LDL) cholesterol 11, 14 • Elevated triglycerides 7, 14 • Low high-density lipoprotein (HDL) cholesterol. This has not been well studied. One case report 24 described the premature development of aortic stenosis in a young man with Tangier disease, a hereditary condition with markedly low HDL levels; the only other report was a cross-sectional analysis that correlated low HDL levels with aortic sclerosis in an elderly cohort. 6 • Elevated lipoprotein(a): Two populationbased studies showed that serum lipoprotein(a) levels closely correlate with the presence of aortic sclerosis, independent of LDL levels. 10, 11 We investigated the concept of an "atheromatous valvulopathy" by examining the lipid profiles of 2,356 patients who underwent aortic valve replacement with or without concomitant coronary bypass grafting. 14 Patients who underwent isolated valve replacement for aortic valve stenosis had significantly higher total cholesterol and LDL cholesterol levels than patients who had valve surgery for aortic regurgitation. These levels were even higher for those who also underwent bypass grafting.
s HISTOLOGIC FEATURES
In the 1970s and 1980s, Pomerance 1 and Roberts 25 described calcification of the aortic cusps that was "preceded by lipoid deposition" and shared "the same etiology as the coronary atherosclerotic plaques." 25 Similarities with coronary disease Otto et al 3 and others 4,26-28 elegantly characterized the histologic features of calcific aortic valve disease.
On gross inspection, diseased aortic valves have areas of irregular thickening and calcification on the aortic side (FIGURE 1). Microscopically, all diseased aortic leaflets reveal disruption of the endothelium on the aortic side.
This process, similar to what occurs in coronary artery disease, 29 constitutes the initial injury to the leaflet, whereby inflammatory cells and cholesterol can enter. Once the endothelium is disrupted, possibly by mechanHigh cholesterol plays a role in aortic stenosis FIGURE 1. Disruption of the endothelium, which also occurs in coronary artery disease, constitutes the initial injury to the leaflet, whereby inflammatory cells and cholesterol can enter. Once the endothelium is disrupted by mechanical stress or other factors, the disease progresses through its various stages of sclerosis and stenosis. ical stress or other factors, the disease progresses through its various stages of sclerosis and stenosis. But regardless of stage, aortic valve lesions demonstrate an overlying disrupted basement membrane with subendothelial accumulation of intracellular and extracellular lipids and lipoproteins. 3, 4 A chronic inflammatory infiltrate is also present, made up of foam cells, non-foam cell macrophages, and T lymphocytes (FIGURE 1) . 3 Additional evidence comes from patients with familial hypercholesterolemia. People who are homozygous for this trait often have premature coronary disease, but aortic valve disease is another common but under-appreciated feature. In these people, lipids infiltrate the aortic cusps and consequently cause them to thicken and stick together, restricting their mobility and rendering the valve stenotic. 20, 21, 30, 31 Aortic valve cusps from homozygotic patients who undergo aortic valve replacement show significant thickening with foam cell deposition surrounded by dystrophic calcification. 31 These findings occur in trileaflet, congenitally normal aortic valves and as early as in the second decade of life.
The regions containing lipoproteins occur at the same location as areas of calcification. 4 From the subendothelium, the lesions extend to the leaflet's central portion, called the fibrosa, and most often involve the base of the leaflet. These findings appear more advanced as the clinical grade of aortic stenosis progresses.
Dissimilarities with coronary disease
Although aortic stenosis and coronary artery lesions share many atheromatous features, there are notable dissimilarities. For example, in aortic valve disease there are fewer smooth muscle cells, and there is more dystrophic calcification. This greater degree of calcification has generated considerable interest in possible specific cellular and, more recently, genetic mechanisms of aortic stenosis.
Osteopontin and other bone proteins have been found in calcified aortic valves. 26, 32 Mohler et al 28 recently reported on the common finding of heterotopic ossification and active bone remodeling in diseased aortic and mitral valves. Lamellar bone was found in 13% of valves with dystrophic calcification.
Recently, Ortlepp et al 33 identified a potential genetic marker for the development of calcific aortic stenosis. In a case-control study, subjects with aortic stenosis had a higher prevalence of the B allele of the gene encoding the vitamin D receptor than of the b allele. This polymorphism has been previously associated with greater bone loss 34 and lower bone density, 35 and these observations led the authors to suggest that the B allele may render a patient more susceptible to dystrophic valvular calcification.
This study may provide a clue to the suggested association between osteoporosis and calcification of the mitral and aortic valves. 9, 11 The exact interaction between this polymorphism, lipids, and inflammation and its role in the development and progression of aortic valve disease remain unclear.
s NONLIPID RISK FACTORS FOR CALCIFIC AORTIC STENOSIS
Hypertension, 6,9,11,22 smoking, 7, 11 and diabetes mellitus 5, 6, 14 have consistently been linked to the development of aortic stenosis, although their exact disease-promoting actions are unclear. Endothelial injury or other processes at work in coronary disease may play a similar role in calcific aortic stenosis.
Other factors that may be associated with aortic valve disease include: • Age [8] [9] [10] [11] 22 • Male sex 7, 11 • Obesity 8 • Uremia 36 • Elevated calcium 37 • Elevated parathyroid hormone 9, 38 • Osteoporosis 9, 11 • Paget disease 39 • Significant renal failure. 36, 40 • The high cardiac-output state, which can coexist with Paget disease and renal failure, may also promote the valvular disease process.
Novel risk factors
Not all patients with risk factors for calcific aortic stenosis develop the condition. Conversely, some patients develop the condition despite having only a few risk factors, so yet-unidentified disease-promoting factors may play a role.
Infectious agents, mainly Chlamydia pneumoniae, stirred interest as possible causes of coronary disease and have also been considered as possible causes or promoters of calcific aortic valve disease. Although the data conflict, most studies found C pneumoniae to be more prevalent in diseased aortic valves than in normal aortic valves. 41, 42 What role this or any other infectious agent plays needs to be better defined. Moreover, whether antibiotic therapy has any effect on slowing the progression of valvular disease is not known.
Elevated homocysteine. Calcific aortic valve disease begins with some form of endothelial injury, and homocysteine can damage the endothelium. Is there a connection?
We recently assessed the association between plasma homocysteine and various 
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degrees of aortic valve disease in 76 surgical patients. 43 The mean homocysteine level was 10.9 µmol/L in patients with normal aortic valves, 11.4 in those with aortic sclerosis, and 15.4 in those with aortic stenosis, but the association was not statistically significant in a multivariate regression model. However, as we anticipated, plasma homocysteine levels were closely associated with increasing age and serum creatinine levels; thus, it is conceivable that the elevated homocysteine levels seen in patients with renal impairment or older age could contribute to the more rapid progression of aortic stenosis observed in these patient populations.
s PREDICTING STENOSIS PROGRESSION
Aortic stenosis tends to progress: the valve area decreases by an average of 0.1 cm 2 per year in this condition, and the transvalvular pressure gradient increases by 6 to 8 mm Hg per year. [44] [45] [46] [47] However, these rates are averages, with wide individual variation. Moreover, it is not currently possible to forecast the progression of aortic sclerosis or stenosis in an individual patient.
Factors associated with progression of stenosis include:
• Increasing age 45, 48, 49 • Male sex 50 • Dyslipidemia 7, [50] [51] [52] • Tobacco use 7, [50] [51] [52] [53] • Hypertension 50 • Diabetes mellitus 50 • Obesity 53 • Elevated serum calcium 51 • Elevated serum creatinine 51 • Aortic valve calcification. 46, 54 These associations are not definitive, as the studies referred to were all either retrospective or relatively small. Further investigation is warranted to pinpoint specific predictors of rapid disease progression.
s EFFECT OF LIPID-LOWERING AGENTS
No medical therapy has yet been proven to alter the natural history of aortic stenosis. Such a therapy would be of considerable importance, as it might delay or even obviate the need for valve replacement in some patients.
What about HMG-coenzyme A reductase inhibitors (statins)? They have been shown to slow the progression of coronary artery disease. Given the similarities of this condition to calcific aortic stenosis, statins might, in theory, reduce the progression of aortic stenosis.
In an observational study, we compared the rate of progression of aortic stenosis in patients who received a statin with those who did not. 49 In 174 patients with mild to moderate calcific aortic stenosis, statin use was a significant independent predictor of a lesser increase in peak gradient and of a smaller decrease in valve area (TABLE 1). The aortic valve area decreased by 0.11 ± 0.18 cm 2 per year in those not taking a statin vs 0.06 ± 0.16 cm 2 in those taking a statin (P = .01 by multivariate analysis).
The association between statin use and slower progression of stenosis has been reproduced in one additional retrospective study in similar patients. 50 These studies seem to justify a prospective trial to substantiate whether drug therapy with statins slows the progression of aortic stenosis. This is currently in progress.
s FUTURE DIRECTIONS
New genetic markers, such as the B allele of the vitamin D receptor, may help us to assess an individual's risk of developing aortic valve disease.
The role of novel cellular components of diseased valves, such as matrix proteins and mast cells, is an area of increasing interest and research.
Potential markers of disease progression, such as C-reactive protein, 55 may be useful tools in deciding the optimal time for valve surgery in patients with mild aortic disease undergoing open-heart surgery for another condition.
